3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
24
Colorectal Neoplasms
16
Small Cell Lung Carcinoma
6
Stomach Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Biliary Tract Neoplasms
4
Sarcoma, Ewing
3
Rhabdomyosarcoma
3
Recurrence
3
Rectal Neoplasms
3
Osteosarcoma
3
Ovarian Neoplasms
2
Nasopharyngeal Carcinoma
2
Glioma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Cholangiocarcinoma
2
Wilms Tumor
1
Weight Loss
1
Triple Negative Breast Neoplasms
1
Somatostatinoma
1
Solid Tumor Cancer
1
Solid Tumor
1
Small Cell Lung Cancer Extensive Stage
1
Small Bowel Adenocarcinoma
1
Sarcoma
1
Rhabdoid Tumor
1
Interventions
Gemcitabine
24
Cisplatin
14
Capecitabine
12
Oxaliplatin
11
Fluorouracil
11
Leucovorin
7
Irinotecan
7
Radiotherapy
5
durvalumab
4
Photochemotherapy
3
Magnetic Resonance Spectroscopy
3
Long-Term Synaptic Depression
3
Erlotinib Hydrochloride
3
Cholangiopancreatography, Endoscopic Retrograde
3
Carboplatin
3
trifluridine tipiracil drug combination
2
regorafenib
2
olaparib
2
ceralasertib
2
Stents
2
Sorafenib
2
Radiosurgery
2
Radiofrequency Ablation
2
Liver Transplantation
2
Filgrastim
2
Dihematoporphyrin Ether
2
1-phenyl-3,3-dimethyltriazene
2
zimberelimab
1
tivozanib
1
titanium silicide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Bile Duct Neoplasms
×
irinotecan sucrosofate
×
Clear all
NCT05277766
2025-07-01
PIPAC-NAL-IRI
University Hospital, Ghent
Phase 1
Recruiting
45 enrolled